CV

Flip AI Launches to Bring the ‘Holy Grail of Observability’ to All Enterprises With $6.5 Million in Seed Funding Led by Factory

Retrieved on: 
Wednesday, November 8, 2023
Cloud, Pentagon, NFL, Intelligence, LLM, Splunk, Innovation, KKR, Neuroscience, National Football League, White House, SVP, Innovative Satellite Technology Demonstration Program, Bedrock, Prometheus, S3, Organization, DevOps, Research, Operational technology, Neon, Special, NLP, OpenSearch, CV, AWS, Data center management, Vserv Digital Services, FMS, ML, EC2, AI, Amazon, Blog, Defense, CPO, Amazon SageMaker, White House Fellows, SAN, Capital, Risk management, Computer data storage, Customer service, Cryptocurrency, New Relic, Factory

Developers and operators spend hours, sometimes days, poring through data and debugging incidents,” said Corey Harrison, co-founder and CEO of Flip AI.

Key Points: 
  • Developers and operators spend hours, sometimes days, poring through data and debugging incidents,” said Corey Harrison, co-founder and CEO of Flip AI.
  • “Our LLM does this heavy lifting in seconds and immediately reduces mean time to detect and remediate critical incidents.
  • which he grew to be the largest consumer facing application in India
    Flip AI Raises Funding from Factory, Morgan Stanley Next Level Fund and GTM Capital
    Today Flip AI also announced $6.5 million in seed funding led by Factory.
  • Read Flip AI’s “Introducing Flip AI” blog: https://www.flip.ai/blog/introducing-flip-ai
    Watch Sunil Mallya’s AWS re:Invent “Train and deploy FMs on Amazon EC2 and Amazon SageMaker, feat.

Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV

Retrieved on: 
Tuesday, November 7, 2023
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, Incidence, Food, Seizure, European Commission, Therapy, CDD, Medication, Hypersalivation, Physician, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Allergen, Somnolence, Epilepsy, CV, CDKL5 deficiency disorder, Marigold, Safety, CDKL5, Patient, Lancet, Pharmaceutical industry, Fever

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY® (ganaxolone) oral suspension CV.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY® (ganaxolone) oral suspension CV.
  • The new program enables physicians to request ZTALMY for eligible patients with seizures associated with CDKL5 deficiency disorder (CDD) in geographies where the product is not commercially available and as supported by local regulatory requirements.
  • The Marinus Access Program will be managed by Durbin, a leader in the international distribution of specialized pharmaceuticals.
  • “Consistent with our company mission, we are committing appropriate resources to help facilitate broader access to ZTALMY for patients with critical unmet medical needs,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.

Lakewood-Amedex Announces Leadership Changes

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Pharmacology, Exact Sciences (company), Bayer, Radiology, Infection, Organic chemistry, Therapy, Shirin David, Drug discovery, Science, technology, engineering, and mathematics, Publication, Drug, Inflammation, Internal medicine, Development, Drug development, Senior, Free University of Berlin, Research and development, University, DRS, Free University, CV, Pharmacy, Agent handling, Cancer, Doctor of Philosophy, Pharmaceutical industry, Management, Nursing, Research, Science, Pfizer

UNIVERSITY PARK, Fla., Nov. 1, 2023 /PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical-stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins™, today announced that Peter B. Corr, Ph.D., who has served as board chairman since 2020, was named Executive Chairman and will assume the strategic responsibilities of former CEO Steve Parkinson who left the company at the request of the Board. Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP. He retired from Pfizer Inc. in 2006 where he was Senior Vice President for Science and Technology, in addition to leading worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development. His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/

Key Points: 
  • Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP.
  • Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development.
  • His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/
    The Company also announced leadership promotions in the organization for Thomas Balzer, M.D., Ph.D., Senior Vice President for Clinical Development, and Kelvin Cooper, Ph.D., Vice President of Research and Development.
  • We look forward to their continued contributions as we work to advance our Research and Clinical Development programs."

NOW AVAILABLE: NEXTBASE iQ, A TRULY SMART, 4G IoT CONNECTED DASH CAM DESIGNED FOR ANY VEHICLE

Retrieved on: 
Monday, October 30, 2023
Internet of things, Insurance, DMS, Amazon (company), Best Buy, Smartphone, CAD, GPS, ADAS, TIME, SOS, Computer vision, Incident report, Drainage, Pedestrian, Solo, POV, Partnership, G-force, LOS, CES, CV, Electronics, K, Human voice, Privacy, Safety, Contextual inquiry, AI, Invention, Intelligence, Consumer electronics, Mobile phone, Rail transport, Nextbase UK

Users can achieve complete vehicle coverage when the iQ is equipped with the optional third rear window mounted POV – the iQ Rear Camera*.

Key Points: 
  • Users can achieve complete vehicle coverage when the iQ is equipped with the optional third rear window mounted POV – the iQ Rear Camera*.
  • "Nextbase iQ is unlike anything on the market today," said Richard Browning, Chief Marketing and Sales Officer for Nextbase.
  • Vehicle Aware (AI-powered ADAS) – improves safe operation of the vehicle and allows drivers to respond accordingly.
  • The Nextbase iQ works hand-in-hand with the all-new Nextbase iQ app, available in app stores now.

Forrester Research Reports 2023 Third-Quarter Financial Results

Retrieved on: 
Thursday, October 26, 2023
Consulting, Professional Services, Business, Finance, CV, Total, FORR, GAAP, Acquisition, Forrester

Forrester Research, Inc. (Nasdaq: FORR) today announced financial results for the third quarter ended September 30, 2023, with flat contract value (CV) at $349.4 million, compared with the prior year.

Key Points: 
  • Forrester Research, Inc. (Nasdaq: FORR) today announced financial results for the third quarter ended September 30, 2023, with flat contract value (CV) at $349.4 million, compared with the prior year.
  • “We continue to improve the Forrester Decisions platform.
  • Adjusted net income excludes stock-based compensation of $4.1 million and amortization of acquisition-related intangible assets of $3.0 million.
  • Forrester is providing updated guidance for 2023 as follows:
    Adjusted financial guidance for the full-year 2023 excludes stock-based compensation expense of $15.0 million to $15.5 million, amortization of acquisition-related intangible assets of approximately $12.0 million, restructuring costs of approximately $12.2 million, a legal settlement of $4.8 million, and any investment gains or losses.

VelocityEHS Awarded Two Patents for Pioneering Use of AI + Machine Learning for EHS & ESG

Retrieved on: 
Thursday, October 26, 2023
MSD, DSM-IV codes, Peter Hancock (professor), Human factors and ergonomics, Patent, Associate, ESG, Computer vision, Safety, Organization, R, Control, Software, Artificial intelligence, Natural language processing, EHS, Machine learning, Risk, Velocity, NLP, Green chemistry, CV, Chemistry, ML, AI, Operational risk, Environmental compliance, Medical device, Health

The patents demonstrate the company’s leadership in developing EHS & ESG technology to drive operational excellence.

Key Points: 
  • The patents demonstrate the company’s leadership in developing EHS & ESG technology to drive operational excellence.
  • Harvesting this data manually is too costly and error-prone for many organizations, meaning they operate without visibility into their full chemical exposure.
  • “For companies serious about safety, sustainability and resilience, these real-world AI applications of ML and NLP bring immediate value.
  • On the VelocityEHS Accelerate® Platform, they have the potential to impact the wellbeing of millions of workers,” said Dr. Julia Penfield, Associate Vice President of Machine Learning.

EQS-News: ams-OSRAM AG: ams OSRAM’s Extraordinary General Meeting approves all voting items incl. capital raise to secure a long-term stable financial base for structural growth

Retrieved on: 
Thursday, October 26, 2023
United Kingdom, Morgan Stanley, Ams-OSRAM, OSRAM, Bank, EGM, US, HSBC, Nature, Growth, Supervisory board, Risk, Prospectus, FMA, European Union (Withdrawal) Act 2018, Representative, UBS AG, UBS, CV, EUR, Accounting, Security (finance), Property management, EU

Premstaetten, Austria and Munich, Germany (20 October 2023) -- ams OSRAM (SIX: AMS), announces that in today’s Extraordinary General Meeting (“EGM”) all voting items on the agenda were approved with majorities of the votes cast ranging from 87.5% to 99.9%.

Key Points: 
  • ams-OSRAM AG: ams OSRAM’s Extraordinary General Meeting approves all voting items incl.
  • capital raise to secure a long-term stable financial base for structural growth
    The issuer is solely responsible for the content of this announcement.
  • capital raise to secure a long-term stable financial base for structural growth
    Premstaetten, Austria and Munich, Germany (20 October 2023) -- ams OSRAM (SIX: AMS), announces that in today’s Extraordinary General Meeting (“EGM”) all voting items on the agenda were approved with majorities of the votes cast ranging from 87.5% to 99.9%.
  • Furthermore, also in accordance with the EGM agenda, Arunjai Mittal was elected as a new member of the Supervisory Board.

Cityview Completes 123-Unit Multifamily Project in West Los Angeles

Retrieved on: 
Friday, October 20, 2023
Bev, Housing, Apollo, LEED, Cooking, High fidelity, Parker, Pet, Wi-Fi, Creativity, Bev Facey Community High School, BBQ, Restaurant, Miracle Mile, Pico-Robertson, CV, Hibachi, Table, Commerce, Nightclub, Film industry

LOS ANGELES, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Cityview , a premier multifamily investment management and development firm, has completed The Parker – a 123-unit mixed-use project in the Pico-Robertson community of West Los Angeles.

Key Points: 
  • LOS ANGELES, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Cityview , a premier multifamily investment management and development firm, has completed The Parker – a 123-unit mixed-use project in the Pico-Robertson community of West Los Angeles.
  • “Located in a highly walkable community near Culver City, Miracle Mile, Beverly Hills and West Hollywood, The Parker fills a severe gap in housing supply in one of the most vibrant cultural and employment centers of Los Angeles,” said Sean Burton, CEO of Cityview.
  • In addition to The Parker, Cityview’s other Los Angeles developments include the recently completed Jasper – a 296-unit opportunity zone project near Downtown Los Angeles.
  • The firm also recently commenced construction on Apollo – a 265-unit multifamily development in Los Angeles’ South Bay - and will complete construction on Belle on Bev - a 243-unit multifamily project in Los Angeles’ Historic Filipinotown (HiFi) – later this year.

London hosts Global Excel Summit 2024

Retrieved on: 
Wednesday, October 25, 2023
Research, Social media, Catalyst Institute of Management and Advance Global Excellence, Innovation, Heart, MVP Baseball (video game series), Formula, Tech, Microsoft, Vue International, Prevalence, Workplace, Institute of Continuing Professional Development, Foot, CPD, Vue, Los Angeles Central Business District, Journal of Business Finance & Accounting, Lambdas, Record, CV, Chandoo Mondeti, Power Query, Video game, Nightclub, Entertainment, Microsoft Excel

LONDON, Oct. 25, 2023 /PRNewswire/ -- The world's biggest Microsoft Excel conference returns next year, as the latest Global Excel Summit instalment takes place 6–8 February 2024.

Key Points: 
  • LONDON, Oct. 25, 2023 /PRNewswire/ -- The world's biggest Microsoft Excel conference returns next year, as the latest Global Excel Summit instalment takes place 6–8 February 2024.
  • Her in-person Opening Keynote at the Global Excel Summit 2024 is a long anticipated-one.
  • Several Excel and Power BI Masterclasses also take place in London and online the day before on 5 February 2024 and the day after the main conference on 9 February 2024.
  • The Global Excel Summit 2024 is sponsored by Zebra BI and crafted by DATEL Productions Ltd in collaboration with Leila Gharani.

GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase

Retrieved on: 
Monday, October 23, 2023
Research, Medical Devices, Technology, Hospitals, Clinical Trials, Science, Surgery, Cardiology, Biotechnology, Other Technology, Other Science, Health, Peter Hancock (professor), Anatomy, 3D, System, BMI, Heart, Life, Interventional cardiology, Prevalence, Rotation, Acquisition, Multimedia, CVD, Radiology, GE, Ecosystem, Freedom, Pulse, CV, Workflow, GE HealthCare, Somatosensory system, TCT, Stent, Cath, Patient, Boston Scientific, Diagnosis, Cardiovascular disease, Pharmaceutical industry, Medical imaging, Allia

Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.

Key Points: 
  • Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.
  • Building on the recent 510(k) clearance of the Allia IGS Pulse system, GE HealthCare will introduce new technologies and solutions at TCT2023 designed to further transform the capabilities of this platform, as well as image guided therapy in cardiology care.
  • In addition to the company’s interventional cardiology showcase at TCT2023, GE HealthCare will also feature the recently launched Vscan Air SL - a wireless handheld ultrasound device for rapid assessments of cardiac and vascular patients.
  • To learn more about GE HealthCare this year at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference (TCT) click here.